(Q37642792)

21 August 2017

1 reference

title

Impact of anti-angiogenic treatments on metastatic renal cell carcinoma (English)

1 reference

21 August 2017

angiogenesis inhibitor

1 reference

Nicola L Ainsworth

1

1 reference

PubMed ID

19954291

21 August 2017

Jean Sz Lee

series ordinal

2

1 reference

PubMed ID

19954291

21 August 2017

Tim Eisen

series ordinal

3

1 reference

21 August 2017

1 December 2009

1 reference

Expert Review of Anticancer Therapy

21 August 2017

1 reference

21 August 2017

9

1 reference

21 August 2017

12

1 reference

21 August 2017

1793-1805

1 reference

The epidemiology of bladder and kidney cancer

21 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Sunitinib efficacy against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

BAY 43-9006: preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Sequential sorafenib and sunitinib for renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Targeted therapy for metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

A distinct expression pattern and point mutation of c-kit in papillary renal cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Overexpression of KIT in chromophobe renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.144

21 January 2018

Identifiers

DOI

10.1586/ERA.09.144

1 reference

21 August 2017

1 reference

PubMed ID

19954291